HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $87 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a Buy rating on Legend Biotech (NASDAQ:LEGN) and maintained an $87 price target.

March 18, 2024 | 10:39 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Legend Biotech has been reiterated with a Buy rating and an $87 price target by HC Wainwright & Co. analyst Mitchell Kapoor.
The reiteration of a Buy rating and maintenance of an $87 price target by a reputable analyst could instill confidence in investors and potentially drive Legend Biotech's stock price upwards in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100